title: Hereditary angioedema: epidemiology, management, and role of icatibant.
abstract: Hereditary angioedema (HAE) is an autosomal dominant, potentially life-threatening condition, manifesting as recurrent and self-limiting episodes of facial, laryngeal, genital, or peripheral swelling with abdominal pain secondary to intra-abdominal edema. The estimated prevalence of HAE in the general population is one individual per 50,000, with reported ranges from 1:10,000 to 1:150,000, without major sex or ethnic differences. Various treatment options for acute attacks and prophylaxis of HAE are authorized and available in the market, including plasma-derived (Berinert®, Cinryze®, and Cetor®) and recombinant (Rhucin® and Ruconest™) C1 inhibitors, kallikrein inhibitor-ecallantide (Kalbitor®), and bradykinin B2 receptor antagonist-icatibant (Firazyr®). Some of these drugs are used only to treat HAE attacks, whereas others are only approved for prophylactic therapies and all of them have improved disease outcomes due to their different mechanisms of action. Bradykinin and its binding to B2 receptor have been demonstrated to be responsible for most of the symptoms of HAE. Thus icatibant (Firazyr®), a bradykinin B2 receptor antagonist, has proven to be an effective and more targeted treatment option and has been approved for the treatment of acute attacks of HAE. Rapid and stable relief from symptoms of cutaneous, abdominal, or laryngeal HAE attacks has been demonstrated by 30 mg of icatibant in Phase III clinical trials. Self-resolving mild to moderate local site reactions after subcutaneous injection of icatibant were observed. Icatibant is a new, safe, and effective treatment for acute attacks of HAE. HAE has been reported to result in enormous humanistic burden to patients, affecting both physical and mental health, with a negative impact on education, career, and work productivity, and with substantial economic burdens. The timely and proper use of disease-specific treatments could improve patients' quality of life, reduce the disease-specific morbidity and mortality, and, last but not least, reduce costs associated with hospitalizations and emergency room visits. Therefore, the paradigm of HAE treatment has the potential to evolve significantly, thereby exponentially improving a patient's quality of life.
authors: University of Texas Medical Branch, Division of Allergy and Clinical Immunology, Galveston, TX, USA.
authors: Aasia
authors: A
authors: Ghazi
authors: J Andrew
authors: JA
authors: Grant
keywords: C1 inhibitor; bradykinin; hereditary angioedema; icatibant
references: Br J Pharmacol. 1991 Mar;102(3):769-73
references: 1364851
references: Allergy Asthma Proc. 2010 Sep-Oct;31(5):407-14
references: 20929608
references: Ann Allergy Asthma Immunol. 2010 Jun;104(6):523-9
references: 20568386
references: Immunol Allergy Clin North Am. 2006 Nov;26(4):709-24
references: 17085286
references: N Engl J Med. 2010 Aug 5;363(6):523-31
references: 20818887
references: N Engl J Med. 2010 Aug 5;363(6):532-41
references: 20818888
references: Am J Emerg Med. 2012 Oct;30(8):1664.e1-2
references: 22100478
references: J Clin Ultrasound. 1999 Nov-Dec;27(9):537-40
references: 10525217
references: Drugs. 2010;70(1):73-81
references: 20030426
references: Ann Allergy Asthma Immunol. 2010 Apr;104(4):314-20
references: 20408341
references: N Engl J Med. 2002 Aug 22;347(8):621-2
references: 12192030
references: J Allergy Clin Immunol. 2000 Dec;106(6):1147-54
references: 11112899
references: Medicine (Baltimore). 1992 Jul;71(4):206-15
references: 1518394
references: Orphanet J Rare Dis. 2011 Jun 17;6:42
references: 21682893
references: Intensive Care Med. 2011 Jul;37(7):1227-8
references: 21484080
references: Postgrad Med. 1998 Apr;103(4):251, 255-6
references: 9553599
references: J Allergy Clin Immunol. 2007 Jun;119(6):1497-503
references: 17418383
references: N Engl J Med. 1996 Jun 20;334(25):1666-7
references: 8628365
references: Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):21
references: 20667124
references: J Eur Acad Dermatol Venereol. 2011 Jan;25(1):119-20
references: 20477917
references: Ann Intern Med. 1976 May;84(5):580-93
references: 1275365
references: J Clin Invest. 2002 Apr;109(8):1057-63
references: 11956243
references: Am J Med. 2006 Mar;119(3):267-74
references: 16490473
references: Lancet. 2000 Jul 15;356(9225):213-7
references: 10963200
references: Arch Intern Med. 2001 Nov 12;161(20):2417-29
references: 11700154
references: Manag Care. 2011 Sep;20(9):44-51
references: 21991862
references: Ann Allergy Asthma Immunol. 2009 Nov;103(5):448
references: 19927548
references: Clin Exp Immunol. 2005 Mar;139(3):379-94
references: 15730382
references: Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):17
references: 20667120
references: Curr Hypertens Rep. 2009 Jun;11(3):178-81
references: 19442326
references: ScientificWorldJournal. 2008 Apr 14;8:384-93
references: 18454246
references: Lancet. 2012 Feb 4;379(9814):474-81
references: 22305226
references: PLoS One. 2013;8(2):e53773
references: 23390491
references: Annu Rev Immunol. 1988;6:595-628
references: 3289579
references: N Engl J Med. 2010 Aug 5;363(6):513-22
references: 20818886
references: J Allergy Clin Immunol. 2004 Sep;114(3):629-37
references: 15356569
references: Allergy Asthma Clin Immunol. 2011 Feb 10;7(1):1
references: 21310025
references: Mayo Clin Proc. 2000 Apr;75(4):349-54
references: 10761488
references: Pharmacoeconomics. 2011 Jan;29(1):63-82
references: 21073206
references: J Allergy Clin Immunol. 2010 Oct;126(4):821-827.e14
references: 20920772
references: Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):22
references: 20667125
references: J Immunol Methods. 2008 Sep 30;338(1-2):14-20
references: 18655790
references: Expert Rev Clin Immunol. 2011 May;7(3):267-72
references: 21595592
references: Allergy. 2012 Feb;67(2):147-57
references: 22126399
references: Am J Gastroenterol. 1995 Mar;90(3):471-4
references: 7872288
references: Clin Exp Dermatol. 2010 Jul;35(5):553-4
references: 20337653
references: J Allergy Clin Immunol. 2009 Oct;124(4):801-8
references: 19767078
references: Am J Med. 1963 Jul;35:37-44
references: 14046003
references: Int Immunopharmacol. 2003 Mar;3(3):311-7
references: 12639808
references: Core Evid. 2012;7:105-14
references: 23055948
references: J Allergy Clin Immunol. 2004 Sep;114(3 Suppl):S51-131
references: 15356535
references: Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):24
references: 20667127
references: Clin Immunol. 2005 Jan;114(1):3-9
references: 15596403
references: Br J Pharmacol. 1991 Mar;102(3):774-7
references: 1364852
references: Ann Emerg Med. 2010 Sep;56(3):278-82
references: 20447725
references: N Engl J Med. 2008 Sep 4;359(10):1027-36
references: 18768946
references: Ann Allergy Asthma Immunol. 2011 Dec;107(6):529-37
references: 22123383
references: Trends Mol Med. 2009 Feb;15(2):69-78
references: 19162547
references: Eur J Pharmacol. 1995 Feb 14;274(1-3):57-64
references: 7768281